Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to $255.6 million.

  • Dianthus Therapeutics' Cash from Financing Activities rose 92640.88% to $274.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.9 million, marking a year-over-year increase of 49.19%. This contributed to the annual value of $255.6 million for FY2024, which is 91.37% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Financing Activities stood at $255.6 million for FY2024, which was up 91.37% from $133.6 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Cash from Financing Activities registered a high of $255.6 million during FY2024, and its lowest value of $67.7 million during FY2020.
  • For the 3-year period, Dianthus Therapeutics' Cash from Financing Activities averaged around $162.0 million, with its median value being $133.6 million (2023).
  • Data for Dianthus Therapeutics' Cash from Financing Activities shows a peak YoY soared of 91.37% (in 2024) over the last 5 years.
  • Over the past 5 years, Dianthus Therapeutics' Cash from Financing Activities (Yearly) stood at $67.7 million in 2020, then surged by 32.27% to $89.6 million in 2021, then rose by 7.90% to $96.7 million in 2022, then skyrocketed by 38.17% to $133.6 million in 2023, then soared by 91.37% to $255.6 million in 2024.